The genus Facklamia emerged on the scientific radar in 1997, introduced through 16S rRNA sequencing. Since its discovery, it has been encountered across various animal sources and, less frequently, as a causative agent of human infections. Facklamia hominis is the most prevalent contributor to human infections among the species within this genus.
Nevertheless, the true extent of its involvement in infections might need to be more reported due to the inherent challenges associated with species identification.While Facklamia hominis infections are relatively rare, they have been linked to invasive diseases, including cases of meningitis and infective endocarditis.
Though infrequent, these occurrences underscore this bacterium’s pathogenic potential in humans. Notably, the literature records only a handful of reported Facklamia hominis infections, with most instances involving adult patients with underlying health conditions such as intravenous drug use, lymphangioma, or prosthetic joint infections.
The geographic reach of Facklamia hominis infections extends across various countries, with documented cases spanning regions including the Mexico, Korea, United States, and Japan. This global presence highlights the importance of vigilance and awareness regarding this pathogen, especially in cases involving individuals with predisposing factors.
Notably, a milestone in the understanding of F. hominis infections was achieved in 2022 when the first documented case of pyelonephritis in a child attributed to this bacterium was published, marking a significant contribution to the understanding of its clinical impact, particularly in pediatric patients.
Classification and Structure:
Kingdom: Bacteria
Phylum: Bacillota
Class: Bacilli
Order: Lactobacillales
Family: Aerococcaceae
Genus:Facklamia
Species:F. hominis
Facklamia hominis is Gram-positive, characterized by a thick peptidoglycan layer in its cell wall that retains the purple stain in the Gram staining method. It is facultative anaerobic; it can grow both in the presence and absence of oxygen.
F. hominis is a coccus exhibiting a spherical or oval shape. It typically forms chains of cells, although it can also appear as single cells or pairs.
This bacterium is relatively small, with an average diameter of approximately 0.5 to 0.8 μm. F. hominis displays alpha-hemolysis, causing partial breakdown of red blood cells in blood agar, leading to a greenish discoloration around its colonies.
Facklamia hominis exhibits a complex surface structure with several antigens, including lipoteichoic acid, peptidoglycan, and capsular polysaccharide. These antigens serve as points of interaction with the host immune system. They can elicit immune responses, triggering the production of antibodies and other defense mechanisms.
Two significant genes associated with Facklamia hominis pathogenesis are hylA and colA. The hylA gene encodes for hyaluronidase, an extracellular enzyme that plays a role in degrading connective tissue. This enzyme can facilitate the invasion of Facklamia hominis into deeper tissues. Similarly, the colA gene encodes collagenase, another enzyme that aids in breaking down collagen, a major component of connective tissue.
Several strains of Facklamia hominis have been identified in various clinical contexts. CIP 105962 and CCUG 36813, isolated from human blood cultures, represent strains associated with bloodstream infections. CCM 4931 was isolated from a human urine sample, indicating its presence in urinary tract-related infections. Additionally, CIP 106072 was isolated from a human vaginal swab, suggesting its potential involvement in genitourinary infections.
Facklamia hominis exhibits a multifaceted pathogenesis, marked by its ability to adhere to mucosal surfaces within the female genital tract and establish biofilms. These biofilms protect against the host’s immune system and antibiotics, making it challenging to eradicate the bacterium.
Furthermore, Facklamia hominis may provoke tissue damage by releasing hemolysins, which can lyse red blood cells and other cells. This damage, coupled with the activation of the host’s innate immune response, contributes to the clinical manifestations of infection.
The invasion of Facklamia hominis into the bloodstream often occurs through disruptions in the mucosal barrier, such as during sexual intercourse, childbirth, or medical instrumentation. Hematogenous spread from other sites of infection, like the urinary or gastrointestinal tract, can also facilitate its entry into the bloodstream.
Once in the bloodstream, the bacterium can disseminate throughout the body, potentially leading to systemic infections.Facklamia hominis employs mechanisms to resist host phagocytic cells, including the production of capsules or slime layers that inhibit opsonization and phagocytosis. It can also survive within phagocytes by escaping from phagosomes or preventing their fusion with lysosomes.
Facklamia hominis may produce factors that degrade or inhibit complement components or bind to host complement regulators to prevent the activation of the complement cascade. Similarly, it can resist antimicrobial peptides by generating proteases that cleave or inactivate them. Alterations in its cell wall or membrane further contribute to antibiotic resistance, reducing the uptake and increasing the efflux of antibiotics. Acquiring resistance genes via horizontal gene transfer adds another layer of resilience to this bacterium, making effective treatment more challenging.
Human host defenses protect the body against microbial threats, including Facklamia hominis. While the specific interactions between the host and this bacterium may not be extensively studied, understanding broader mechanisms of mucosal immunity can shed light on how the body combats such infections.
α-Defensins: These small peptides are vital components of the body’s defense mechanisms. They are found in various tissues, including neutrophils and Paneth cells in the small intestine. α-Defensins, such as HNP1–3, are antimicrobial peptides that can exhibit broad-spectrum activity against bacteria, fungi, and even some viruses. In the female genital tract, α-defensins have been identified in the cervix and vagina. They may play a role in protecting against infections, although the specific interactions with Facklamia hominis require further investigation.
Lactoferrin: Lactoferrin is another essential protein with antimicrobial properties. It serves a dual purpose by sequestering iron, essential for microbial growth, and through direct antimicrobial activity. While its concentration in vaginal fluid is relatively low, it can still contribute to the defense against various pathogens, including Facklamia hominis.
Lysozyme: Lysozyme is an enzyme that can hydrolyze peptidoglycan, a component of bacterial cell walls. It also possesses nonenzymatic antimicrobial activity due to its cationic nature, which allows it to disrupt microbial membranes. In the cervical mucus plug, lysozyme can reach high concentrations and contribute to microbial defense.
Other Factors: The female genital tract has unique defense mechanisms, including antimicrobial peptides and proteins like secretory leukocyte protease inhibitor (SLPI). These components can inhibit microbial growth and may play a role in protecting against infections.
Clinical presentations of Facklamia hominis infections are infrequent and contingent upon the specific site of infection. Reported symptoms encompass fever, abdominal pain, vaginal discharge, pelvic inflammatory disease, endometritis, postpartum sepsis, wound inflammation, osteomyelitis, and cardiac valve damage.
Facklamia hominis is an uncommon pathogen known to cause human infections, with a notable predilection for the female genitourinary tract. This microorganism can give rise to a spectrum of clinical manifestations, some of which include:
Pyelonephritis: Pyelonephritis represents an infection affecting the kidneys, characterized by symptoms like fever, frequent urination, and vesical tenesmus. Remarkably, the case we are discussing here marks the first recorded instance of pyelonephritis caused by Facklamia hominis in a child and the second case of such an infection in a pediatric patient.
Chorioamnionitis: Chorioamnionitis is an infection involving the placenta and fetal membranes, typically manifesting with symptoms like maternal fever, fetal tachycardia, and uterine tenderness. An instance of Facklamia hominis-associated chorioamnionitis has been recorded in a pregnant woman who presented with pyrexia and clinical signs indicative of infection.
Facklamia hominis has also been implicated in a range of other invasive diseases, including but not limited to meningitis, endocarditis, peritonitis, and abscess formation. These cases underscore the versatility of this pathogen in causing a variety of severe medical conditions beyond those mentioned earlier.
Diagnosing Facklamia hominis infection involves combining laboratory techniques and clinical assessments to ensure accurate identification and effective treatment. Here are the essential methods used for diagnosis:
Culture test: Culturing F. hominis involves growing the bacteria on specialized laboratory media, such as blood agar or chocolate agar. After 48 hours of incubation, F. hominis typically forms small colonies with alpha-hemolysis, the partial lysis of red blood cells, seen as a greenish zone around the colonies. However, it’s important to note that culture alone may not always be reliable for F. hominis identification, as it can sometimes be mistaken for other Gram-positive cocci, like viridans group streptococci or enterococci.
Biochemical Tests:Facklamia hominis can be characterized through a series of biochemical tests. It is catalase-negative, oxidase-negative, and indole-negative. It can ferment glucose, lactose, and sucrose, but it cannot ferment mannitol or sorbitol. Additionally, it can hydrolyze esculin and hippurate but cannot break down gelatin or starch.
MALDI-TOF Mass Spectrometry: MALDI-TOF MS is a valuable technique used for bacterial identification. It analyzes the protein profile of bacteria and can identify Facklamia hominis with a high confidence level, provided it is available in the reference database. This rapid and highly accurate method makes it preferable over traditional culture for Facklamia hominis identification.
16S rRNA Gene Sequencing: Molecular methods, such as PCR and DNA sequencing of the 16S ribosomal RNA gene, can also be employed to confirm the identity of Facklamia hominis. This method compares the bacterial gene sequence to reference databases and is considered the gold standard for bacterial identification. However, it may be more time-consuming and costly compared to MALDI-TOF MS.
Other Tests: Based on the clinical presentation and the suspected site of infection, healthcare providers may recommend additional tests such as urine analysis, blood tests, imaging studies, or tissue biopsy. These tests help assess the severity and extent of the infection & rule out other potential causes of symptoms.
Practicing safe sex and using condoms can significantly avoid the burden of sexually transmitted infections, including those caused by Facklamia hominis. This preventive measure is crucial for minimizing the transmission of the bacterium.
Before undergoing urological or gynecological procedures that potentially introduce Facklamia hominis into the urinary tract or bloodstream, healthcare providers may prescribe prophylactic antibiotics. These antibiotics help prevent infection, particularly in individuals at higher risk due to the invasive nature of the procedures.
Maintaining excellent personal hygiene is fundamental in preventing the spread of Facklamia hominis. Frequent handwashing, especially before handling food or touching the face, can reduce the risk of contamination and transmission of the bacterium. This measure is essential to curb its spread in community settings.
The genus Facklamia emerged on the scientific radar in 1997, introduced through 16S rRNA sequencing. Since its discovery, it has been encountered across various animal sources and, less frequently, as a causative agent of human infections. Facklamia hominis is the most prevalent contributor to human infections among the species within this genus.
Nevertheless, the true extent of its involvement in infections might need to be more reported due to the inherent challenges associated with species identification.While Facklamia hominis infections are relatively rare, they have been linked to invasive diseases, including cases of meningitis and infective endocarditis.
Though infrequent, these occurrences underscore this bacterium’s pathogenic potential in humans. Notably, the literature records only a handful of reported Facklamia hominis infections, with most instances involving adult patients with underlying health conditions such as intravenous drug use, lymphangioma, or prosthetic joint infections.
The geographic reach of Facklamia hominis infections extends across various countries, with documented cases spanning regions including the Mexico, Korea, United States, and Japan. This global presence highlights the importance of vigilance and awareness regarding this pathogen, especially in cases involving individuals with predisposing factors.
Notably, a milestone in the understanding of F. hominis infections was achieved in 2022 when the first documented case of pyelonephritis in a child attributed to this bacterium was published, marking a significant contribution to the understanding of its clinical impact, particularly in pediatric patients.
Classification and Structure:
Kingdom: Bacteria
Phylum: Bacillota
Class: Bacilli
Order: Lactobacillales
Family: Aerococcaceae
Genus:Facklamia
Species:F. hominis
Facklamia hominis is Gram-positive, characterized by a thick peptidoglycan layer in its cell wall that retains the purple stain in the Gram staining method. It is facultative anaerobic; it can grow both in the presence and absence of oxygen.
F. hominis is a coccus exhibiting a spherical or oval shape. It typically forms chains of cells, although it can also appear as single cells or pairs.
This bacterium is relatively small, with an average diameter of approximately 0.5 to 0.8 μm. F. hominis displays alpha-hemolysis, causing partial breakdown of red blood cells in blood agar, leading to a greenish discoloration around its colonies.
Facklamia hominis exhibits a complex surface structure with several antigens, including lipoteichoic acid, peptidoglycan, and capsular polysaccharide. These antigens serve as points of interaction with the host immune system. They can elicit immune responses, triggering the production of antibodies and other defense mechanisms.
Two significant genes associated with Facklamia hominis pathogenesis are hylA and colA. The hylA gene encodes for hyaluronidase, an extracellular enzyme that plays a role in degrading connective tissue. This enzyme can facilitate the invasion of Facklamia hominis into deeper tissues. Similarly, the colA gene encodes collagenase, another enzyme that aids in breaking down collagen, a major component of connective tissue.
Several strains of Facklamia hominis have been identified in various clinical contexts. CIP 105962 and CCUG 36813, isolated from human blood cultures, represent strains associated with bloodstream infections. CCM 4931 was isolated from a human urine sample, indicating its presence in urinary tract-related infections. Additionally, CIP 106072 was isolated from a human vaginal swab, suggesting its potential involvement in genitourinary infections.
Facklamia hominis exhibits a multifaceted pathogenesis, marked by its ability to adhere to mucosal surfaces within the female genital tract and establish biofilms. These biofilms protect against the host’s immune system and antibiotics, making it challenging to eradicate the bacterium.
Furthermore, Facklamia hominis may provoke tissue damage by releasing hemolysins, which can lyse red blood cells and other cells. This damage, coupled with the activation of the host’s innate immune response, contributes to the clinical manifestations of infection.
The invasion of Facklamia hominis into the bloodstream often occurs through disruptions in the mucosal barrier, such as during sexual intercourse, childbirth, or medical instrumentation. Hematogenous spread from other sites of infection, like the urinary or gastrointestinal tract, can also facilitate its entry into the bloodstream.
Once in the bloodstream, the bacterium can disseminate throughout the body, potentially leading to systemic infections.Facklamia hominis employs mechanisms to resist host phagocytic cells, including the production of capsules or slime layers that inhibit opsonization and phagocytosis. It can also survive within phagocytes by escaping from phagosomes or preventing their fusion with lysosomes.
Facklamia hominis may produce factors that degrade or inhibit complement components or bind to host complement regulators to prevent the activation of the complement cascade. Similarly, it can resist antimicrobial peptides by generating proteases that cleave or inactivate them. Alterations in its cell wall or membrane further contribute to antibiotic resistance, reducing the uptake and increasing the efflux of antibiotics. Acquiring resistance genes via horizontal gene transfer adds another layer of resilience to this bacterium, making effective treatment more challenging.
Human host defenses protect the body against microbial threats, including Facklamia hominis. While the specific interactions between the host and this bacterium may not be extensively studied, understanding broader mechanisms of mucosal immunity can shed light on how the body combats such infections.
α-Defensins: These small peptides are vital components of the body’s defense mechanisms. They are found in various tissues, including neutrophils and Paneth cells in the small intestine. α-Defensins, such as HNP1–3, are antimicrobial peptides that can exhibit broad-spectrum activity against bacteria, fungi, and even some viruses. In the female genital tract, α-defensins have been identified in the cervix and vagina. They may play a role in protecting against infections, although the specific interactions with Facklamia hominis require further investigation.
Lactoferrin: Lactoferrin is another essential protein with antimicrobial properties. It serves a dual purpose by sequestering iron, essential for microbial growth, and through direct antimicrobial activity. While its concentration in vaginal fluid is relatively low, it can still contribute to the defense against various pathogens, including Facklamia hominis.
Lysozyme: Lysozyme is an enzyme that can hydrolyze peptidoglycan, a component of bacterial cell walls. It also possesses nonenzymatic antimicrobial activity due to its cationic nature, which allows it to disrupt microbial membranes. In the cervical mucus plug, lysozyme can reach high concentrations and contribute to microbial defense.
Other Factors: The female genital tract has unique defense mechanisms, including antimicrobial peptides and proteins like secretory leukocyte protease inhibitor (SLPI). These components can inhibit microbial growth and may play a role in protecting against infections.
Clinical presentations of Facklamia hominis infections are infrequent and contingent upon the specific site of infection. Reported symptoms encompass fever, abdominal pain, vaginal discharge, pelvic inflammatory disease, endometritis, postpartum sepsis, wound inflammation, osteomyelitis, and cardiac valve damage.
Facklamia hominis is an uncommon pathogen known to cause human infections, with a notable predilection for the female genitourinary tract. This microorganism can give rise to a spectrum of clinical manifestations, some of which include:
Pyelonephritis: Pyelonephritis represents an infection affecting the kidneys, characterized by symptoms like fever, frequent urination, and vesical tenesmus. Remarkably, the case we are discussing here marks the first recorded instance of pyelonephritis caused by Facklamia hominis in a child and the second case of such an infection in a pediatric patient.
Chorioamnionitis: Chorioamnionitis is an infection involving the placenta and fetal membranes, typically manifesting with symptoms like maternal fever, fetal tachycardia, and uterine tenderness. An instance of Facklamia hominis-associated chorioamnionitis has been recorded in a pregnant woman who presented with pyrexia and clinical signs indicative of infection.
Facklamia hominis has also been implicated in a range of other invasive diseases, including but not limited to meningitis, endocarditis, peritonitis, and abscess formation. These cases underscore the versatility of this pathogen in causing a variety of severe medical conditions beyond those mentioned earlier.
Diagnosing Facklamia hominis infection involves combining laboratory techniques and clinical assessments to ensure accurate identification and effective treatment. Here are the essential methods used for diagnosis:
Culture test: Culturing F. hominis involves growing the bacteria on specialized laboratory media, such as blood agar or chocolate agar. After 48 hours of incubation, F. hominis typically forms small colonies with alpha-hemolysis, the partial lysis of red blood cells, seen as a greenish zone around the colonies. However, it’s important to note that culture alone may not always be reliable for F. hominis identification, as it can sometimes be mistaken for other Gram-positive cocci, like viridans group streptococci or enterococci.
Biochemical Tests:Facklamia hominis can be characterized through a series of biochemical tests. It is catalase-negative, oxidase-negative, and indole-negative. It can ferment glucose, lactose, and sucrose, but it cannot ferment mannitol or sorbitol. Additionally, it can hydrolyze esculin and hippurate but cannot break down gelatin or starch.
MALDI-TOF Mass Spectrometry: MALDI-TOF MS is a valuable technique used for bacterial identification. It analyzes the protein profile of bacteria and can identify Facklamia hominis with a high confidence level, provided it is available in the reference database. This rapid and highly accurate method makes it preferable over traditional culture for Facklamia hominis identification.
16S rRNA Gene Sequencing: Molecular methods, such as PCR and DNA sequencing of the 16S ribosomal RNA gene, can also be employed to confirm the identity of Facklamia hominis. This method compares the bacterial gene sequence to reference databases and is considered the gold standard for bacterial identification. However, it may be more time-consuming and costly compared to MALDI-TOF MS.
Other Tests: Based on the clinical presentation and the suspected site of infection, healthcare providers may recommend additional tests such as urine analysis, blood tests, imaging studies, or tissue biopsy. These tests help assess the severity and extent of the infection & rule out other potential causes of symptoms.
Practicing safe sex and using condoms can significantly avoid the burden of sexually transmitted infections, including those caused by Facklamia hominis. This preventive measure is crucial for minimizing the transmission of the bacterium.
Before undergoing urological or gynecological procedures that potentially introduce Facklamia hominis into the urinary tract or bloodstream, healthcare providers may prescribe prophylactic antibiotics. These antibiotics help prevent infection, particularly in individuals at higher risk due to the invasive nature of the procedures.
Maintaining excellent personal hygiene is fundamental in preventing the spread of Facklamia hominis. Frequent handwashing, especially before handling food or touching the face, can reduce the risk of contamination and transmission of the bacterium. This measure is essential to curb its spread in community settings.
The genus Facklamia emerged on the scientific radar in 1997, introduced through 16S rRNA sequencing. Since its discovery, it has been encountered across various animal sources and, less frequently, as a causative agent of human infections. Facklamia hominis is the most prevalent contributor to human infections among the species within this genus.
Nevertheless, the true extent of its involvement in infections might need to be more reported due to the inherent challenges associated with species identification.While Facklamia hominis infections are relatively rare, they have been linked to invasive diseases, including cases of meningitis and infective endocarditis.
Though infrequent, these occurrences underscore this bacterium’s pathogenic potential in humans. Notably, the literature records only a handful of reported Facklamia hominis infections, with most instances involving adult patients with underlying health conditions such as intravenous drug use, lymphangioma, or prosthetic joint infections.
The geographic reach of Facklamia hominis infections extends across various countries, with documented cases spanning regions including the Mexico, Korea, United States, and Japan. This global presence highlights the importance of vigilance and awareness regarding this pathogen, especially in cases involving individuals with predisposing factors.
Notably, a milestone in the understanding of F. hominis infections was achieved in 2022 when the first documented case of pyelonephritis in a child attributed to this bacterium was published, marking a significant contribution to the understanding of its clinical impact, particularly in pediatric patients.
Classification and Structure:
Kingdom: Bacteria
Phylum: Bacillota
Class: Bacilli
Order: Lactobacillales
Family: Aerococcaceae
Genus:Facklamia
Species:F. hominis
Facklamia hominis is Gram-positive, characterized by a thick peptidoglycan layer in its cell wall that retains the purple stain in the Gram staining method. It is facultative anaerobic; it can grow both in the presence and absence of oxygen.
F. hominis is a coccus exhibiting a spherical or oval shape. It typically forms chains of cells, although it can also appear as single cells or pairs.
This bacterium is relatively small, with an average diameter of approximately 0.5 to 0.8 μm. F. hominis displays alpha-hemolysis, causing partial breakdown of red blood cells in blood agar, leading to a greenish discoloration around its colonies.
Facklamia hominis exhibits a complex surface structure with several antigens, including lipoteichoic acid, peptidoglycan, and capsular polysaccharide. These antigens serve as points of interaction with the host immune system. They can elicit immune responses, triggering the production of antibodies and other defense mechanisms.
Two significant genes associated with Facklamia hominis pathogenesis are hylA and colA. The hylA gene encodes for hyaluronidase, an extracellular enzyme that plays a role in degrading connective tissue. This enzyme can facilitate the invasion of Facklamia hominis into deeper tissues. Similarly, the colA gene encodes collagenase, another enzyme that aids in breaking down collagen, a major component of connective tissue.
Several strains of Facklamia hominis have been identified in various clinical contexts. CIP 105962 and CCUG 36813, isolated from human blood cultures, represent strains associated with bloodstream infections. CCM 4931 was isolated from a human urine sample, indicating its presence in urinary tract-related infections. Additionally, CIP 106072 was isolated from a human vaginal swab, suggesting its potential involvement in genitourinary infections.
Facklamia hominis exhibits a multifaceted pathogenesis, marked by its ability to adhere to mucosal surfaces within the female genital tract and establish biofilms. These biofilms protect against the host’s immune system and antibiotics, making it challenging to eradicate the bacterium.
Furthermore, Facklamia hominis may provoke tissue damage by releasing hemolysins, which can lyse red blood cells and other cells. This damage, coupled with the activation of the host’s innate immune response, contributes to the clinical manifestations of infection.
The invasion of Facklamia hominis into the bloodstream often occurs through disruptions in the mucosal barrier, such as during sexual intercourse, childbirth, or medical instrumentation. Hematogenous spread from other sites of infection, like the urinary or gastrointestinal tract, can also facilitate its entry into the bloodstream.
Once in the bloodstream, the bacterium can disseminate throughout the body, potentially leading to systemic infections.Facklamia hominis employs mechanisms to resist host phagocytic cells, including the production of capsules or slime layers that inhibit opsonization and phagocytosis. It can also survive within phagocytes by escaping from phagosomes or preventing their fusion with lysosomes.
Facklamia hominis may produce factors that degrade or inhibit complement components or bind to host complement regulators to prevent the activation of the complement cascade. Similarly, it can resist antimicrobial peptides by generating proteases that cleave or inactivate them. Alterations in its cell wall or membrane further contribute to antibiotic resistance, reducing the uptake and increasing the efflux of antibiotics. Acquiring resistance genes via horizontal gene transfer adds another layer of resilience to this bacterium, making effective treatment more challenging.
Human host defenses protect the body against microbial threats, including Facklamia hominis. While the specific interactions between the host and this bacterium may not be extensively studied, understanding broader mechanisms of mucosal immunity can shed light on how the body combats such infections.
α-Defensins: These small peptides are vital components of the body’s defense mechanisms. They are found in various tissues, including neutrophils and Paneth cells in the small intestine. α-Defensins, such as HNP1–3, are antimicrobial peptides that can exhibit broad-spectrum activity against bacteria, fungi, and even some viruses. In the female genital tract, α-defensins have been identified in the cervix and vagina. They may play a role in protecting against infections, although the specific interactions with Facklamia hominis require further investigation.
Lactoferrin: Lactoferrin is another essential protein with antimicrobial properties. It serves a dual purpose by sequestering iron, essential for microbial growth, and through direct antimicrobial activity. While its concentration in vaginal fluid is relatively low, it can still contribute to the defense against various pathogens, including Facklamia hominis.
Lysozyme: Lysozyme is an enzyme that can hydrolyze peptidoglycan, a component of bacterial cell walls. It also possesses nonenzymatic antimicrobial activity due to its cationic nature, which allows it to disrupt microbial membranes. In the cervical mucus plug, lysozyme can reach high concentrations and contribute to microbial defense.
Other Factors: The female genital tract has unique defense mechanisms, including antimicrobial peptides and proteins like secretory leukocyte protease inhibitor (SLPI). These components can inhibit microbial growth and may play a role in protecting against infections.
Clinical presentations of Facklamia hominis infections are infrequent and contingent upon the specific site of infection. Reported symptoms encompass fever, abdominal pain, vaginal discharge, pelvic inflammatory disease, endometritis, postpartum sepsis, wound inflammation, osteomyelitis, and cardiac valve damage.
Facklamia hominis is an uncommon pathogen known to cause human infections, with a notable predilection for the female genitourinary tract. This microorganism can give rise to a spectrum of clinical manifestations, some of which include:
Pyelonephritis: Pyelonephritis represents an infection affecting the kidneys, characterized by symptoms like fever, frequent urination, and vesical tenesmus. Remarkably, the case we are discussing here marks the first recorded instance of pyelonephritis caused by Facklamia hominis in a child and the second case of such an infection in a pediatric patient.
Chorioamnionitis: Chorioamnionitis is an infection involving the placenta and fetal membranes, typically manifesting with symptoms like maternal fever, fetal tachycardia, and uterine tenderness. An instance of Facklamia hominis-associated chorioamnionitis has been recorded in a pregnant woman who presented with pyrexia and clinical signs indicative of infection.
Facklamia hominis has also been implicated in a range of other invasive diseases, including but not limited to meningitis, endocarditis, peritonitis, and abscess formation. These cases underscore the versatility of this pathogen in causing a variety of severe medical conditions beyond those mentioned earlier.
Diagnosing Facklamia hominis infection involves combining laboratory techniques and clinical assessments to ensure accurate identification and effective treatment. Here are the essential methods used for diagnosis:
Culture test: Culturing F. hominis involves growing the bacteria on specialized laboratory media, such as blood agar or chocolate agar. After 48 hours of incubation, F. hominis typically forms small colonies with alpha-hemolysis, the partial lysis of red blood cells, seen as a greenish zone around the colonies. However, it’s important to note that culture alone may not always be reliable for F. hominis identification, as it can sometimes be mistaken for other Gram-positive cocci, like viridans group streptococci or enterococci.
Biochemical Tests:Facklamia hominis can be characterized through a series of biochemical tests. It is catalase-negative, oxidase-negative, and indole-negative. It can ferment glucose, lactose, and sucrose, but it cannot ferment mannitol or sorbitol. Additionally, it can hydrolyze esculin and hippurate but cannot break down gelatin or starch.
MALDI-TOF Mass Spectrometry: MALDI-TOF MS is a valuable technique used for bacterial identification. It analyzes the protein profile of bacteria and can identify Facklamia hominis with a high confidence level, provided it is available in the reference database. This rapid and highly accurate method makes it preferable over traditional culture for Facklamia hominis identification.
16S rRNA Gene Sequencing: Molecular methods, such as PCR and DNA sequencing of the 16S ribosomal RNA gene, can also be employed to confirm the identity of Facklamia hominis. This method compares the bacterial gene sequence to reference databases and is considered the gold standard for bacterial identification. However, it may be more time-consuming and costly compared to MALDI-TOF MS.
Other Tests: Based on the clinical presentation and the suspected site of infection, healthcare providers may recommend additional tests such as urine analysis, blood tests, imaging studies, or tissue biopsy. These tests help assess the severity and extent of the infection & rule out other potential causes of symptoms.
Practicing safe sex and using condoms can significantly avoid the burden of sexually transmitted infections, including those caused by Facklamia hominis. This preventive measure is crucial for minimizing the transmission of the bacterium.
Before undergoing urological or gynecological procedures that potentially introduce Facklamia hominis into the urinary tract or bloodstream, healthcare providers may prescribe prophylactic antibiotics. These antibiotics help prevent infection, particularly in individuals at higher risk due to the invasive nature of the procedures.
Maintaining excellent personal hygiene is fundamental in preventing the spread of Facklamia hominis. Frequent handwashing, especially before handling food or touching the face, can reduce the risk of contamination and transmission of the bacterium. This measure is essential to curb its spread in community settings.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
